Research location
Fano
Italy
Advertisement
Research activity in Fano
ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 19 trials and 19 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Fano
19 linked trials · page 1 of 1Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126 · 2025-10-24 · 1 site observation
RECRUITING
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)NCT06757634 · 2025-07-24 · 1 site observation
RECRUITING
A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 DiabetesNCT06113341 · 2024-11-07 · 1 site observation
WITHDRAWN
A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With NeratinibNCT05599334 · 2022-07-05 · 1 site observation
COMPLETED
An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 DiabetesNCT03786406 · 2018-12-03 · 1 site observation
COMPLETED
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung CancerNCT02633189 · 2016-04-01 · 1 site observation
UNKNOWN
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerNCT02120417 · 2014-05-01 · 1 site observation
TERMINATED
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing RegimenNCT01254279 · 2010-12-01 · 1 site observation
COMPLETED
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic CancerNCT01000025 · 2009-12-23 · 1 site observation
COMPLETED
Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLINNCT00831909 · 2009-01-01 · 1 site observation
COMPLETED
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast CancerNCT00528567 · 2007-12-01 · 1 site observation
COMPLETED
Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for EtanerceptNCT00459706 · 2007-09-01 · 1 site observation
COMPLETED
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DNCT00490139 · 2007-05-16 · 1 site observation
COMPLETED
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.NCT00448279 · 2007-04-01 · 1 site observation
COMPLETED
Local Phase 4 Pan-European SMART StudyNCT00463866 · 2007-03-01 · 1 site observation
COMPLETED
TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung CancerNCT00349219 · 2006-12-01 · 1 site observation
COMPLETED
Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast CancerNCT00296010 · 2005-08-01 · 1 site observation
TERMINATED
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing ChemotherapyNCT02761642 · 2004-02-29 · 1 site observation
COMPLETED
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLCNCT00234468 · 2004-01-01 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.